The SPDR S&P 500 ETF Trust posted a 1.21% gain in July, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.97%. The top 15 dividend growth stocks for August 2024 offer an average dividend yield of 1.49% and appear to be about 28% undervalued based on dividend yield theory. Since its inception in September 2020, the watchlist has achieved a 12.25% annualized return.

INDIANAPOLIS--(BUSINESS WIRE)--Irvington Prep Academy in Indianapolis unveiled first ever weight room, fitness space, provided by Elevance Health and Impact Fitness Foundation.

Elevance Health's health insurance segment is well diversified, with a meaningful exposure to commercial services-only memberships and Medicaid. ELV has been doing a great job handling the current environment of rising medical costs. The Healthcare Services segment is starting to meaningfully grow external revenue.

Wednesday, Elevance Health Inc.  ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.

Elevance Health, Inc. has shown remarkable dividend growth in the past decade, exceeding revenue and EPS expectations for the first quarter. Elevance's balance sheet remains A-rated, and shares of the stock could be undervalued by 14%. The company is positioned to generate over 30% cumulative total returns through 2026, making it a high-quality investment option.

Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.

Elevance Health, Inc. (NYSE:ELV ) Q2 2024 Earnings Call Transcript July 17, 2024 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO Mark Kaye - CFO Felicia Norwood - President, Government Health Benefits Pete Haytaian - President, Carelon Morgan Kendrick - President, Commercial Health Benefits Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Lance Wilkes - Bernstein Kevin Fischbeck - Bank of America Josh Raskin - Nephron Research Lisa Gill - JPMorgan Justin Lake - Wolfe Research Erin Wright - Morgan Stanley Michael Ha - Baird Andrew Mok - Barclays Ryan Langston - Cowen Stephen Baxter - Wells Fargo Scott Fidel - Stephens Sarah James - Cantor Fitzgerald George Hill - Deutsche Bank Whit Mayo - Leerink Partners Dave Windley - Jefferies Ann Hynes - Mizuho Securities Ben Hendrix - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Second Quarter Earnings Conference Call.

Elevance Health (ELV) topped analyst expectations with its second-quarter results, but shares of the health insurance provider fell in intraday trading Wednesday amid declining Medicaid membership.

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health Inc.  ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.

Elevance Health (ELV) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.99 per share. This compares to earnings of $9.04 per share a year ago.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.